Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 274

Sort by

Sort Order Select

Journal Articles

Measurable Residual Disease by Mass Spectrometry and Next-Generation Flow to Assess Treatment Response in Myeloma

Blood blood.2024024995.

https://doi.org/10.1182/blood.2024024995

Published: 2024

Includes: Supplemental data

Journal Articles

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Blood (2024) 143 (17): 1713–1725.

https://doi.org/10.1182/blood.2023021567

Published: 2024

Includes: Supplemental data

Journal Articles

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

Blood (2024) 143 (7): 597–603.

https://doi.org/10.1182/blood.2023022083

Published: 2024

Includes: Supplemental data

Journal Articles

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Blood (2023) 142 (Supplement 1): 62.

https://doi.org/10.1182/blood-2023-183029

Published: 2023

Journal Articles

Assessment of Artificial Intelligence Language Models and Information Retrieval Strategies for QA in Hematology

Maria R Cervera, David Bermejo-Peláez, Miguel Gómez-Álvarez, Marta Hidalgo Soto, Ana Mendoza-Martínez, Adriana Oñós Clausell, Oscar Darias, Jaime García-Villena, Celina Benavente Cuesta, Julia Montoro, Joaquin Martínez-López, Miguel Luengo-Oroz

Blood (2023) 142 (Supplement 1): 7175.

https://doi.org/10.1182/blood-2023-178528

Published: 2023

Journal Articles

Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 1461.

https://doi.org/10.1182/blood-2023-186265

Published: 2023

Journal Articles

Clinical Significance of Measurable Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Chimeric Antigen Receptor (CAR) T Cells and T-Cell Engagers (TCE)

Aintzane Zabaleta, Noemi Puig, Maria Teresa Cedena Romero, Jose J Perez, Cristina Moreno, Luis-Esteban Tamariz-Amador, Paula Rodriguez Otero, Veronica Gonzalez-Calle, Lucia Lopez Corral, Beatriz Rey-Búa, Borja Puertas Martínez, Fatima Miras, Jose Sanchez-Pina, Nieves Lopez, Joaquin Martinez-Lopez, Maria Victoria Mateos, Jesus San-Miguel, Bruno Paiva

Blood (2023) 142 (Supplement 1): 94.

https://doi.org/10.1182/blood-2023-185980

Published: 2023

Journal Articles

Intracytoplasmatic BCMA Point Mutation and Teclistamab Resistance: Genomic Assessment of a Multidrug-Resistant Multiple Myeloma Patient

Natalia Buenache Cuenda, Hipolito Nicolas Cuesta Hernández, Alicia Giménez Sánchez, Laura Carneros Blanco, Juan Manuel Rosa-Rosa, Yanira Ruiz-Heredia, Enrique Revilla, Seungbin Han, Umair Munawar, Inmaculada Rapado, Rosa Ayala, K. Martin Kortüm, Antonio Valeri, Santiago Barrio, Joaquin Martinez Lopez, Larissa Haertle

Blood (2023) 142 (Supplement 1): 1925.

https://doi.org/10.1182/blood-2023-184824

Published: 2023

Journal Articles

Parallel Monitoring of Measurable Residual Disease and Chimerism By NGS in Myelodysplastic Syndrome after Allogenic STEM Cell Transplant

Irene Zamanillo, Santiago Barrio, Alejandro Martín-Muñoz, Sara Dorado, Ana K Ballesteros, Yanira Ruiz-Heredia, Margarita Rodriguez, Carolina Martinez-Laperche, Sandra Martín, Blanca Ferrer Lores, Ivan Martin Castillo, Inmaculada Rapado, Rosa Ayala, Joaquin Martinez-Lopez, Maria Teresa Cedena Romero

Blood (2023) 142 (Supplement 1): 6781.

https://doi.org/10.1182/blood-2023-188600

Published: 2023

Journal Articles

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

Blood (2023) 142 (18): 1518–1528.

https://doi.org/10.1182/blood.2022019531

Published: 2023

Journal Articles

GEM2017FIT Trial: Induction Therapy with Bortezomib-Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) Versus Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus/Minus Daratumumab (D), 18 Cycles, Followed By Consolidation and Maintenance Therapy with Lenalidomide and Daratumumab: Phase III, Multicenter, Randomized Trial for Elderly Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients Aged between 65 and 80 Years

Blood (2023) 142 (Supplement 1): 209.

https://doi.org/10.1182/blood-2023-179866

Published: 2023

Journal Articles

Laboratories Can Reliably Detect Clinically Relevant Variants in the TP53 Gene below 10 % Allelic Frequency: A Multicenter Study of ERIC, the European Research Initiative on CLL

Sarka Pavlova, Jitka Malcikova, Lenka Radova, Silvia Bonfiglio, Jack B. Cowland, Christian Brieghel, Mette Klarskov Andersen, Maria Karypidou, Bella V Biderman, Michael Doubek, Gregory Lazarian, Inmaculada Rapado, Matthijs Vynck, Naomi Porret, Martin Andres, Dina Rosenberg, Dvora Sahar, Carolina Martinez-Laperche, Ismael Buño Borde, Andrew Hindley, Julio Bravo Sánchez, José García-Marco, Alicia Serrano, Blanca Ferrer Lores, Concepción Fernández-Rodriguez, Beatriz Bellosillo, Stephan Stilgenbauer, Eugen Tausch, Hero Nikdin, Fiona Quinn, Emer Atkinson, Lisette Van De Corput, Cafer Yildiz, Cristina Bilbao, Yanira Florido, Christian Thiede, Caroline Schuster, Anastazja Stoj, Sylwia Czekalska, Anastasia Chatzidimitriou, Stamatia Laidou, Audrey Bidet, Charles Dussiau, Friedel Nollet, Giovanna Piras, Tereza Borosova, Terezia Kurucova, Maria Monne, Svetlana Smirnova, Evgeny Nikitin, Ivan Sloma, Marie-Helene Delfau, Laetitia Largeaud, Loic Ysebaert, Peter J. M. Valk, Amy Christian, Renata Walewska, Marta Sebastião, Maria Gomes da Silva, Piero Galieni, Mario Angelini, Davide Rossi, Valeria Spina, Sónia Matos, Vânia Martins, David Donaldson, Tomasz Stoklosa, Monika Pepek, Panagiotis Baliakas, Rafa Andreu, Irene Luna, Tiina Kahre, Ülle Murumets, Sophie Laird, Daniel Ward, Miguel Alcoceba, Ana Balanzategui, Lydia Scarfo, Francesca Gandini, Ettore Zapparoli, Adoracion Blanco, Pau Abrisqueta Costa, Ana E. Rodriguez, Maria Rocio Benito Sanchez, Frédéric Davi, Clothilde Bravetti, Paula Gameiro, Joaquin Martinez-Lopez, Barbara Tazon, Fanny Baran-Marszak, Zadie Davies, Mark Caterwood, Andrey B Sudarikov, Richard Rosenquist, Carsten Utoft Niemann, Kostas Stamatopoulos, Paolo Ghia, Sarka Pospisilova

Blood (2023) 142 (Supplement 1): 200.

https://doi.org/10.1182/blood-2023-173235

Published: 2023

Journal Articles

Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease

Blood (2023) 142 (Supplement 1): 1958.

https://doi.org/10.1182/blood-2023-179452

Published: 2023

Journal Articles

Minimally Invasive Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma (MM)

Blood (2023) 142 (Supplement 1): 339.

https://doi.org/10.1182/blood-2023-186916

Published: 2023

Journal Articles

A High Percentage of DNAM-1+ and Low Percentage of Tactile+ NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema Trial

Blood (2023) 142 (Supplement 1): 2960.

https://doi.org/10.1182/blood-2023-189676

Published: 2023

Journal Articles

Biological and Clinical Significance of Undetectable Circulating Tumor Cells (CTCs) in Patients (Pts) with Multiple Myeloma (MM)

Blood (2023) 142 (Supplement 1): 646.

https://doi.org/10.1182/blood-2023-186411

Published: 2023

Journal Articles

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

Blood (2023) 142 (Supplement 1): 645.

https://doi.org/10.1182/blood-2023-182964

Published: 2023

Journal Articles

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

Blood (2023) 142 (Supplement 1): 2854.

https://doi.org/10.1182/blood-2023-186277

Published: 2023

Journal Articles

30-Minute Infusion of Isatuximab in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Results of a Phase 1b Study

Enrique M Ocio, Aurore Perrot, Philippe Moreau, Maria-Victoria Mateos, Sara Bringhen, Joaquin Martinez-Lopez, Lionel Karlin, Igor Wolfgang Blau, Song-Yau Wang, Maurizio Martelli, Corina Oprea, Yvonne Dong, Ercem Kodas, Jesus San Miguel

Blood (2023) 142 (Supplement 1): 6717.

https://doi.org/10.1182/blood-2023-175020

Published: 2023

Journal Articles

Functional Characterization of GPRC5D alteration and Its Impact on Talquetamab Resistance in Relapsed/ Refractory Multiple Myeloma

Seungbin Han, Umair Munawar, Larissa Haertle, Cornelia Vogt, Silvia Nerreter, Eva Teufel, Xiang Zhou, Max Steinhardt, Florian Eisele, Peter Raab, Marietta Truger, Sara Dorado, Santiago Barrio, Claudia Haferlach, Joaquin Martínez-López, Hermann Einsele, Leo Rasche, Johannes M Waldschmidt, K. Martin Kortüm

Blood (2023) 142 (Supplement 1): 3323.

https://doi.org/10.1182/blood-2023-181607

Published: 2023

NARROW

Measurable Residual Disease by Mass Spectrometry and Next-Generation Flow to Assess Treatment Response in Myeloma

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Assessment of Artificial Intelligence Language Models and Information Retrieval Strategies for QA in Hematology

Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia

Clinical Significance of Measurable Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Chimeric Antigen Receptor (CAR) T Cells and T-Cell Engagers (TCE)

Intracytoplasmatic BCMA Point Mutation and Teclistamab Resistance: Genomic Assessment of a Multidrug-Resistant Multiple Myeloma Patient

Parallel Monitoring of Measurable Residual Disease and Chimerism By NGS in Myelodysplastic Syndrome after Allogenic STEM Cell Transplant

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

Laboratories Can Reliably Detect Clinically Relevant Variants in the TP53 Gene below 10 % Allelic Frequency: A Multicenter Study of ERIC, the European Research Initiative on CLL

Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease

Minimally Invasive Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma (MM)

A High Percentage of DNAM-1+ and Low Percentage of Tactile+ NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema Trial

Biological and Clinical Significance of Undetectable Circulating Tumor Cells (CTCs) in Patients (Pts) with Multiple Myeloma (MM)

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

30-Minute Infusion of Isatuximab in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Results of a Phase 1b Study

Functional Characterization of GPRC5D alteration and Its Impact on Talquetamab Resistance in Relapsed/ Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only